If the body creates b-cells which turns into autoantibodies that attacks an enzyme that is required for the metabolic system to function properly then Rituximab is surely a very interesting drug to consider using. If the phase 3 trial shows a response rate of 50% for patients treated with rituximab, compared to say 10-20% for placebo group, that would be a fantastic result.
Most absurd thing I've read in 2017. Where do you get your information? I don't want to be rude, but I think you have read up on why immunomodulatory drugs like rituximab works in diseases. It is 100% certain that all of us wont benefit from rituximab, but I think we know from a fact that quite a few of us would. We don't know how many before the study is published in early 2018, but the researchers are confident that a group of patients with ME respond to the drug. It would be great if they actually could link B-cell depletion to the believed metabolic dysfunction, but if they are on the wrong that it doesn't really make any difference for the rituximab study. We use many drugs that we don't know exactly why they work. The important thing with respect to treatment is that patients that receive the drug improves more than the placebo group, and that side effects are not an issue. Even why we don't know why it helps, if we're certain that rituximab does alleviate symptoms for ME patients, then we have something that can help many of us.
I would also have a look at their latest presentation in Norwich which is available here:
I think it would be fairer to say that, apart from Kogelnik and the German one (sorry, I can´t spell German names), none of the other researchers seem very keen on looking at Rituximab as a treatment before we have actually determined what the problem is, which is exactly how I feel. Others (particularly those who are more ill tan me) may feel quite differently.